Wolfgang Dohle
Research Associate
My research focuses on anti-cancer drug design using synthetic organic chemistry as the main tool. Tetrahydroisoquinoline derivatives with excellent physicochemical properties were developed as a new class of microtubule disruptors showing very good activity against various cancer cells lines including some taxane-resistant ones.
One of our most potent compound to date, STX3451 could also provide a new approach for inducing cell death and lowering tumour burden in NF1 and other hormone responsive cancers with limited treatment options. More recently, my research focus has shifted towards the synthesis of anti-bacterial compounds and inositol adenophostin derivatives.
Key publications
-
Synthesis, antitubulin, and antiproliferative SAR of analogues of 2-methoxyestradiol-3,17-O,O-bis-sulfamate.
Journal article
Jourdan F. et al, (2010), J Med Chem, 53, 2942 - 2951
-
Structure-activity relationships of C-17-substituted estratriene-3-O-sulfamates as anticancer agents.
Journal article
Jourdan F. et al, (2011), J Med Chem, 54, 4863 - 4879
-
Steroidomimetic Tetrahydroisoquinolines for the Design of New Microtubule Disruptors.
Journal article
Leese MP. et al, (2012), ACS Med Chem Lett, 3, 5 - 9
-
Tetrahydroisoquinolinone-based steroidomimetic and chimeric microtubule disruptors.
Journal article
Leese MP. et al, (2014), ChemMedChem, 9, 85 - 1
-
Synthesis, antitubulin, and antiproliferative SAR of C3/C1-substituted tetrahydroisoquinolines.
Journal article
Dohle W. et al, (2014), ChemMedChem, 9, 350 - 370
-
Synthesis, anti-tubulin and antiproliferative SAR of steroidomimetic dihydroisoquinolinones.
Journal article
Leese MP. et al, (2014), ChemMedChem, 9, 798 - 812
-
Optimisation of tetrahydroisoquinoline-based chimeric microtubule disruptors.
Journal article
Dohle W. et al, (2014), ChemMedChem, 9, 1783 - 1793
-
Targeted NF1 cancer therapeutics with multiple modes of action: small molecule hormone-like agents resembling the natural anticancer metabolite, 2-methoxyoestradiol.
Journal article
Shen Y-C. et al, (2015), Br J Cancer, 113, 1158 - 1167
Recent publications
-
Targeted NF1 cancer therapeutics with multiple modes of action: small molecule hormone-like agents resembling the natural anticancer metabolite, 2-methoxyoestradiol.
Journal article
Shen Y-C. et al, (2015), Br J Cancer, 113, 1158 - 1167
-
Optimisation of tetrahydroisoquinoline-based chimeric microtubule disruptors.
Journal article
Dohle W. et al, (2014), ChemMedChem, 9, 1783 - 1793